This report on global infectious disease treatment market studies the increasing demand for infectious disease treatment due to rise in the drug resistant bacterial strain, early disease diagnosis and treatment and promising drug pipeline.

For the purpose of this study, the infectious disease treatment market is segmented into therapeutics (Antibacterial drugs, Antiviral drugs, Antifungal drugs, Antiparasitic drugs) and application type (AIDS, Hepatitis B, Hepatitis C, HPV, MRSA, CT/NG and Others).

The pipeline analysis for global infectious disease treatment market comprises projected market sales of Phase III anti-infective drugs estimated till 2029. We have estimated sales of very specific molecules based on the type (Imipenem/Cilastatin+relebactum, (MK-7655), S-033188, Cadazolid, Baxdela (Delafloxacin), GS-9620 (TLR-7 agonist), Doravirine (MK-1439), ZERBAXA (MK-7625A)), are the drugs in the pipeline which are anticipated to be launched during the forecast period.

The geographic segmentation of the global infectious disease treatment market is performed for the regions North America, Europe, Asia Pacific, Latin America and Middle East and Africa markets. The regions are also further sub-segmented on the basis of major countries. 

Therapeutics type analysis

Factors such as rising prevalence of infectious disease, technological advancement in the anti-infective drug formulation for e.g. (Ciprofloxacin Hydrochloride effervescent tablets have more gastro-retention than Ciprofloxacin Hydrochloride tablets) and rising demand for personalized medication promotes the demand for infectious disease treatment market. Antibacterial drugs holds the largest market due to increasing prevalence of bacterial infection, rise in the number of drug resistant bacterial strain will propel the demand for higher antibiotics. Antiviral drugs are anticipated to register faster growth due to high public awareness of sexually transmitted diseases such as HIV, HPV and Gonorrhea, and technological advancement in the formulation of antivirals with least side effects for e.g. (Zidovudine an antiretroviral drug is available as an IV formulation to surpass adverse effects such as nausea and vomiting in pregnant women). Overall, the global infectious disease treatment market is highly competitive with presence of multiple players like Abbott Laboratories, Johnson and Johnson, Hoffman-La Roche AG, Alere, Inc. etc. specializing in respective fields. Consolidation activities are being increasingly witnessed on the competitive front with a view to increase the technological advancement in the infectious disease treatment market.

Application Analysis

Human Papillomavirus (HPV) held the largest market in the application segment, according to World Health Organization approximately 290 million (1995-2005) women suffered with HPV infection. The growth is attributed mainly due to increasing prevalence of HPV infection, high public awareness and early disease diagnosis. Hospital acquired Methicillin-resistant Staphylococcus aureus infection (MRSA) will be the fastest growing market due to the increase in number of MRSA infection in hospitals, medication lapse, unhygienic conditions in hospitals and use of non-sterilized surgical devices, and unnecessary use of antibiotics etc.

North America was observed as the largest market for infectious disease treatment in the base year 2020. According to Centre for Disease Control and Prevention in 2019 about 39,513 new cases of human acquired immune deficiency syndrome (HIV). The growth is attributed mainly due to increasing prevalence of infectious disease, public awareness and early disease diagnosis and supportive reimbursement policies. Europe is expected to be the second largest market due to rising public awareness related with early disease diagnosis, improved healthcare infrastructure, government and non-government organizations arranging awareness activities and camps. Growth of Asia Pacific for infectious disease treatment market is attributed by factors like rising prevalence of infectious disease, increasing investments in drug R&D and higher disposable income in these regions. However, factors such as developing health infrastructure, increasing awareness among people about health care and tapping potential market in the remote areas to fuel the rapid growth of infectious disease treatment market in Latin America and Middle East and Africa region in the near future.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Infectious Disease Treatment market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Infectious Disease Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Infectious Disease Treatment market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Infectious Disease Treatment market?
• Which is the largest regional market for Infectious Disease Treatment market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Infectious Disease Treatment market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Infectious Disease Treatment market worldwide?